Ocuphire Pharma price target lowered to $10 from $18 at Canaccord

Canaccord lowered the firm’s price target on Ocuphire Pharma (OCUP) to $10 from $18 and keeps a Buy rating on the shares. The firm noted they announced they will acquire Opus Genetics in all-stock transaction, gaining seven gene therapy programs for inherited retinal disease and will trade under a new symbol “IRD” on October 24th.